NCT04420923Active, not recruiting
Optimizing the Treatment Strategy for Age-related Macular Degeneration
A Randomised Controlled Trial Testing the Efficacy of the Treatment Strategy Observe-and-Plan Against Standard Treat-and-Extend in a Population of Newly Referred Patients With Age-related Macular Degeneration.
Source: ClinicalTrials.gov · Last updated 8 Jun 2025
Brief summary (registry, in English)
The purpose of this study is to compare two different treatment protocols for wet macular degeneration; the new protocol called "Observe and Plan" against the current standard protocol "Treat and Extend". Studies suggest that patients achieve equally good visual acuity with fewer controls and that they are more satisfied with the new protocol.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 4 Jun 2020
- Start date
- 20 May 2020
- Primary completion date
- 30 Sept 2025
- Lead sponsor
- St. Olavs Hospital
- Diseases
- Macular degeneration
- NCT number
- NCT04420923
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 20 May 2020 to the primary completion date, 30 Sept 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Eyes formerly treated with anti-VEGF, photodynamic therapy, radiation therapy, transpupillary thermotherapy or focal laser photocoagulation involving the macular area.
Other illness
- Any other ongoing eye disease that influences patient's visual acuity, such as glaucoma with central vision loss, proliferative diabetic retinopathy, diabetic macular edema or chronic uveitis.
Other
- Geographic atrophy and subretinal fibrosis affecting the patient's visual acuity.
Who the study is looking for
- diagnosed age-related macular degeneration according to criteria.
- new diagnose of active CNV verified with OCTA or FA / ICGA.
- BCVA ≥ 20/200 measured with ETDRS visual acuity chart
- written informed consent
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ålesund Hospital Coordinator of this site? Confirm its status | Ålesund | Norway | Unknown status |
| Molde Hospital Coordinator of this site? Confirm its status | Molde | Norway | Unknown status |
| Dept. of Ophthalmology, St Olavs Hospital, Trondheim University Hospital Coordinator of this site? Confirm its status | Trondheim | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.